Human VEGF-C Alexa Fluor® 350-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # AF752U
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Applications for Human VEGF-C Alexa Fluor® 350-conjugated Antibody
ELISA
Immunohistochemistry
Western Blot
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: VEGF-C
Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a VEGF sub-family that share the conserved VEGF homology domain (VHD) with other VEGF family members but are distinguished by their preferential formation of non-covalent homodimers. Both VEGF-C and -D have long N- and C-terminal propeptide extensions. The VEGF-C propeptide undergoes stepwise proteolytic processing to generate ligands with increasing affinity for VEGF-R3. However, only the fully processed VEGF-C containing just the VHD can bind VEGF-R2. None of the VEGF-C forms have appreciable affinity for VEGF-R1. VEGF-C is expressed in multiple adult human tissues, most prominently in lymph nodes, heart, placenta, ovary, and small intestine. Traces of VEGF-C are also detected in brain, liver, thymus, skeletal muscles, spleen, prostate, testis and colon. Unlike other VEGF family members, VEGF-C expression is not regulated by hypoxia. VEGF-C is a lymphangiogenic growth factor and the VEGF-C/VEGF-R3 signaling pathway has been shown to be crucial for lymphangiogenesis. VEGF-C and VEGF-R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. VEGF-C stimulates lymphangiogenesis in the avian chorioallantoic membrane model. Over-expression of VEGF-C in breast cancer cells has been shown to increase intratumoral lymphangiogenesis, resulting in enhanced metastasis to regional lymph nodes and to the lungs. Mouse tumors expressing elevated levels of VEGF-C have increased lymphatic metastasis and increased lymphatic surface area in the tumor margin. VEGF-C is also associated with lymph node metastasis of colorectal carcinoma. Besides lymphangiogenesis, VEGF-C can have potent effects on physiological angiogenesis through its interaction with VEGF R2. The protein can stimulate migration and proliferation of endothelial cells in vitro and in vivo and has been shown to stimulate angiogenesis in the mouse cornea and in rabbit hind limb ischaemia.
Long Name
Alternate Names
Gene Symbol
Additional VEGF-C Products
Product Specific Notices for Human VEGF-C Alexa Fluor® 350-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only